Click to copy
Press release content from BusinessWire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Acceleron to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference

January 2, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 2, 2019--Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that Habib Dable, President and Chief Executive Officer, will present an overview of the company along with its upcoming corporate priorities at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:00 p.m. PST / 5:00 p.m. EST in San Francisco, California.

In addition, the Company will webcast the question and answer breakout session immediately following its presentation at 2:30 p.m. PST / 5:30 p.m. EST.

The live webcast of the presentation and breakout session can be accessed on the Investors page of the Company’s website at www.acceleronpharma.com. A replay of the webcast will be available approximately two hours after the event on the Acceleron website.

About Acceleron

Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company’s leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body’s ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190102005112/en/

CONTACT: Todd James, IRC, 617-649-9393

Vice President, Investor Relations and Corporate Communications



Matt Fearer, 617-301-9557

Director, Corporate Communications



SOURCE: Acceleron Pharma Inc.

Copyright Business Wire 2019.

PUB: 01/02/2019 07:00 AM/DISC: 01/02/2019 07:01 AM


All contents © copyright 2019 The Associated Press. All rights reserved.